Inventor
CLARKE ADAM
AU18 patents
⚠️ This page may combine multiple inventors who share the name “CLARKE ADAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
8 patentsUS10822422B2Nov 3, 2020
Antibodies against TL1a and uses thereof
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD10 citations81
US9611322B2Apr 4, 2017
Fusions of antibodies to CD38 and attenuated interferon alpha
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD6 citations81
US10544199B2Jan 28, 2020
Interferon alpha 2B variants
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD7 citations79
US10981986B2Apr 20, 2021
Fusions of antibodies to CD38 and attenuated interferon alpha
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD2 citations70
US9963515B2May 8, 2018
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD5 citations70
US11319356B2May 3, 2022
Interferon alpha 2B variants
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD2 citations68
US11117975B2Sep 14, 2021
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD1 citations60
US12410256B2Sep 9, 2025
Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD0 citations59
CEPHALON LLC
5 patentsUS11725052B2Aug 15, 2023
Anti-PAR-2 antibodies and methods of use thereof
CEPHALON LLC2 citations65
US12577298B2Mar 17, 2026
Anti-IL-5 antibodies
CEPHALON LLC0 citations58
US12018084B2Jun 25, 2024
Anti-CXCR2 antibodies and uses thereof
CEPHALON LLC0 citations56
US12384841B2Aug 12, 2025
Anti-PAR-2 antibodies and methods of use thereof
CEPHALON LLC0 citations55
US12358980B2Jul 15, 2025
Compositions and methods for anti-PACAP antibodies
CEPHALON LLC0 citations50